Translational Controversies: Utility of MRD and ctDNA in Breast Cancer
Session Details
Moderator
David Cescon, Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada
Presentation numberCT2-01
Is MRD Ready for Prime Time?
Nick Turner, Royal Marsden, London, United Kingdom
Presentation numberCT2-02
ctDNA Guided Endpoints in Metastatic Disease
Jo Chien, UCSF, San Francisco, CA
Presentation numberCT2-03
Endpoints in Modern Clinical Trials
Yu Shyr, Vanderbilt University School of Medicine, Nashville, TN
Presentation numberCT2-04
Navigating MRD Testing: Partnering with Patients to Optimize Care
Patricia A Spears, University of North Carolina, Chapel Hill, NC